3 citations
,
April 2012 in “Journal of the American Academy of Dermatology” Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.
1 citations
,
January 2026 in “International Journal of Dermatology” Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.
August 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
January 2022 in “Al-Azhar Medical Journal” Higher antigliadin antibody levels are linked to alopecia areata severity.
February 2026 in “International Journal of Pharmaceutics”
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
9 citations
,
January 2023 in “Dermatology and therapy” A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.
1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
2 citations
,
June 2022 in “Journal of cosmetic dermatology” Dupilumab can help hair regrowth but may also trigger alopecia areata.
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” July 2025 in “Skin Appendage Disorders” Dutasteride microinfusion and microneedling both effectively treat male hair loss.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
3 citations
,
August 2024 in “British Journal of Dermatology” Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
3 citations
,
August 2024 in “Cureus” Upadacitinib may cause hair loss.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
February 2024 in “Drug Delivery and Translational Research” A new liposomal formulation improves drug delivery and hair growth for treating hair loss without causing skin irritation.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
April 2024 in “Skin research and technology” Minoxidil with triamcinolone acetonide is more effective for mild alopecia areata when injected with microneedles than when applied topically.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Amalaki improves cholesterol, blood sugar, inflammation, and liver function without serious side effects.
2 citations
,
May 2023 in “The Journal of Immunology” NXC736 significantly reduced hair loss in mice with alopecia areata.
June 2024 in “Frontiers in immunology” Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Amalaki improves health in many areas, including cholesterol, blood sugar, and liver function, with no serious side effects.